Reported 3 days ago
Lexeo Therapeutics has received encouragement from the FDA for an Accelerated Approval pathway for its gene therapy candidate LX2006, aimed at treating Friedreich ataxia/FA cardiomyopathy. The company shared promising interim data from ongoing Phase I/II trials and plans to initiate a pivotal study in H1 2026, contingent upon meeting additional regulatory requirements and utilizing their optimized manufacturing process.
Source: YAHOO